Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 33

Sort by

Sort Order Select

Journal Articles

Efficacy and Safety of Frontline Bortezomib, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (VR-CAP) Vs R-CHOP in a Subset of Newly Diagnosed Mantle Cell Lymphoma (MCL) Patients (Pts) Medically Eligible for Transplantation in the Randomized Phase 3 LYM-3002 Study (NCT00722137)

Johannes Drach, MD, Huiqiang Huang, MD, Olga S Samoilova, MD, Andrew Belch, MD, Charles M. Farber, MD PhD, André Bosly, MD PhD, Jan Novak, MD PhD, Jan Zaucha, MD PhD, Angela Dascalescu, MD PhD, Udomsak Bunworasate, MD, Zvenyslava Masliak, MD PhD, Kateryna Vilchevskaya, MD PhD, Tadeusz Robak, MD, Lixia Pei, PhD, Brendan Rooney, PhD, Helgi van de Velde, MD PhD, Franco Cavalli, MD

Blood (2014) 124 (21): 3064.

https://doi.org/10.1182/blood.V124.21.3064.3064

Published: 2014

Journal Articles

Updated Efficacy and Safety, and Exploratory Ki-67 Results For The MCL-001 Study Of Lenalidomide In Mantle Cell Lymphoma Patients Who Relapsed Or Were Refractory To Bortezomib

Andre Goy, MD, Michael E. Williams, MD, ScM, Sevgi Kalayoglu Besisik, MD, Johannes Drach, Radhakrishnan Ramchandren, MD, Michael J. Robertson, MD, Irit Avivi, MD, Jacob M Rowe, MD, Raoul Herbrecht, MD, Achiel Van Hoof, Miklos Egyed, Lei Zhang, Sherri Cicero, Tommy Fu, Carla Heise, PhD, Thomas E Witzig, MD

Blood (2013) 122 (21): 3057.

https://doi.org/10.1182/blood.V122.21.3057.3057

Published: 2013

Journal Articles

Phase II Multicenter Study of Single-Agent Lenalidomide in Subjects with Mantle Cell Lymphoma Who Relapsed or Progressed After or Were Refractory to Bortezomib: The MCL-001 “EMERGE” Study

Andre Goy, MD, Rajni Sinha, MD, MRCP, Michael E. Williams, M.D., Sevgi Kalayoglu Besisik, Johannes Drach, Radhakrishnan Ramchandren, MD, Michael J. Robertson, MD, Irit Avivi, MD, Jacob M. Rowe, Raoul Herbrecht, MD, Achiel Van Hoof, Miklos Egyed, MD, PhD, Lei Zhang, MD, Sherri Cicero, Tommy Fu, Thomas E. Witzig, MD

Blood (2012) 120 (21): 905.

https://doi.org/10.1182/blood.V120.21.905.905

Published: 2012

Journal Articles

Induction Therapy with Novel Agents Improves Relapse-Free Survival After Autologous Stem-Cell Transplantation in Multiple Myeloma

Sandra Eder, Wolfgang Lamm, Michaela Gruber, Beatrice Schauer, Jutta Ackermann, Heinz Gisslinger, Johannes Drach

Blood (2011) 118 (21): 4494.

https://doi.org/10.1182/blood.V118.21.4494.4494

Published: 2011

Journal Articles

Bortezomib Administered Subcutaneously Is Well Tolerated in Bortezomib-Based Combination Regimens Used in Patients with Multiple Myeloma and AL Amyloidosis

Wolfgang Lamm, Beatrice Schauer, Sandra Eder, Christoph Zielinski, Johannes Drach

Blood (2011) 118 (21): 5124.

https://doi.org/10.1182/blood.V118.21.5124.5124

Published: 2011

Journal Articles

UDP Glucuronosyltransferase 2B17 Double Deletion Genotype Is An Independent Marker for Poor Prognosis In Multiple Myeloma

Michaela Gruber, Sandra Eder, Trang Le, Jutta Ackermann, Katrina Vanura, Ulrich Jaeger, Johannes Drach

Blood (2010) 116 (21): 2955.

https://doi.org/10.1182/blood.V116.21.2955.2955

Published: 2010

Journal Articles

Secretome Analyses of Primary Bone Marrow Fibroblasts Isolated From MGUS and Multiple Myeloma Show a Stepwise Occurrence of Alterations.

Johannes Drach, MD, Astrid Slany, Thomas Mohr, Johannes Griss, Christoph C Zielinski, Christopher Gerner

Blood (2009) 114 (22): 1801.

https://doi.org/10.1182/blood.V114.22.1801.1801

Published: 2009

Journal Articles

Efficacy and Safety of Retreatment with Bortezomib in Patients with Multiple Myeloma: Interim Results From RETRIEVE, a Prospective International Phase 2 Study.

Maria Teresa Petrucci, Igor W. Blau, Paolo Corradini, Meletios A. Dimopoulos, Johannes Drach, Pilar Giraldo, Adriana Teixeira, Joan Blade

Blood (2009) 114 (22): 3866.

https://doi.org/10.1182/blood.V114.22.3866.3866

Published: 2009

Journal Articles

Efficacy of the Combination of Bortezomib and Dexamethasone in Systemic AL Amyloidosis.

Wolfgang Lamm, Wolfgang Willenbacher, Niklas Zojer, Ercan Müldür, Heinz Ludwig, Alois Lang, Christoph C Zielinski, Johannes Drach

Blood (2009) 114 (22): 2871.

https://doi.org/10.1182/blood.V114.22.2871.2871

Published: 2009

Journal Articles

Thalidomide-Interferon Vs. Interferon Maintenance Therapy After Thal-Dex Vs. MP Induction Therapy in Elderly Patients with Multiple Myeloma.

Heinz Ludwig, MD, Zdenek Adam, MD, Elena Tóthová, MD, Roman Hajek, MD, Boris Labar, MD, PhD, Miklós Egyed, MD, PhD, Ivan Spicka, MD, Johannes Drach, MD, Heinz Gisslinger, MD, Ingrid Kuhn, MD, Niklas Zojer, MD, Zoran Birovljev, Axel Hinke, PhD

Blood (2009) 114 (22): 2891.

https://doi.org/10.1182/blood.V114.22.2891.2891

Published: 2009

Journal Articles

Thalidomide-dexamethasone compared with melphalan-prednisolone in elderly patients with multiple myeloma

Heinz Ludwig, Roman Hajek, Elena Tóthová, Johannes Drach, Zdenek Adam, Boris Labar, Miklós Egyed, Ivan Spicka, Heinz Gisslinger, Richard Greil, Ingrid Kuhn, Niklas Zojer, Axel Hinke

Blood (2009) 113 (15): 3435–3442.

https://doi.org/10.1182/blood-2008-07-169565

Published: 2009

Journal Articles

Double Transplantation with Melphalan (200 mg/m 2 ) Compared with Triple Transplantation with Intermediate Dose Melphalan (100 mg/m 2 ) in Patients with Multiple Myeloma

Heinz Ludwig, MD, Ivan Spicka, MD, Werner Linkesch, MD, Richard Greil, Hedwig Kasparu, MD, Eberhard Gunsilius, MD, Josef Thaler, MD, Johannes Drach, MD, Ingrid Kuhn, MD, Adalbert Weiβmann, MD, Axel Hinke, PhD

Blood (2008) 112 (11): 3317.

https://doi.org/10.1182/blood.V112.11.3317.3317

Published: 2008

Journal Articles

Two-Monthly Rituximab Infusions Maintain Target Concentrations: Pharmacokinetic Data of the AGMT-NHL9 Maintenance Study in Patients with Follicular Lymphoma in Complete or Partial Remission.

Ulrich Jaeger, MD, Otto Krieger, MD, Georg Hopfinger, MD, Cathrin Skrabs, MD, Christine Einberger, Veronika Huter, MD, Hubert Hausmaninger, MD, Johannes Drach, MD, Markus Raderer, MD, Michael Woo, Pharm.D, Helen Melzer, PhD, Richard Greil, MD, Michael A Fridrik, MD

Blood (2008) 112 (11): 1997.

https://doi.org/10.1182/blood.V112.11.1997.1997

Published: 2008

Journal Articles

Predictive Value of D-Dimer Levels for Venous Thromboembolism in Cancer Patients: Results from the Vienna Cancer and Thrombosis Study (CATS)

Cihan Ay, MD, Rainer Vormittag, MD, Daniela Dunkler, PhD, Ralph Simanek, MD, Alexandru-Laurentiu Chiriac, MD, Johannes Drach, MD, Peter Quehenberger, MD, Oswald Wagner, MD, Christoph Zielinski, MD, Ingrid Pabinger, MD

Blood (2008) 112 (11): 3824.

https://doi.org/10.1182/blood.V112.11.3824.3824

Published: 2008

Journal Articles

Efficacy and Safety of Re-Treatment with Bortezomib (Velcade©) in Patients with Multiple Myeloma: Results from a Prospective International Phase II Trial

Maria Teresa Petrucci, Igor W. Blau, PD, Paolo Corradini, MD, Meletios A. Dimopoulos, Johannes Drach, MD, Pilar Giraldo, MD, PhD, Adriana Teixeira, MD, Joan Blade

Blood (2008) 112 (11): 3690.

https://doi.org/10.1182/blood.V112.11.3690.3690

Published: 2008

Journal Articles

A Cellular Proteome Map of Human Multiple Myeloma.

Johannes Drach, MD, Astrid Slany, Verena Sagaster, MD, Nina Gundacker, Verena Haudek, Viktoria Odelga, Helge Wimmer, Christoph Zielinski, MD, Christopher Gerner, MD

Blood (2007) 110 (11): 111.

https://doi.org/10.1182/blood.V110.11.111.111

Published: 2007

Journal Articles

Bortezomib, Rituximab, and Dexamethason (BORID) as Salvage Treatment in Relapsed/Refractory Mantle Cell Lymphoma: Sustained Disease Control in Patients Achieving a Complete Remission.

Johannes Drach, MD, Hannes Kaufmann, MD, Oskar Pichelmayer, MD, Verena Sagaster, MD, Sonja Holzer, MD, Viktoria Odelga, MD, Christoph Zielinski, MD, Markus Raderer, MD

Blood (2007) 110 (11): 2578.

https://doi.org/10.1182/blood.V110.11.2578.2578

Published: 2007

Journal Articles

Thalidomide-Dexamethasone vs. Melphalan-Prednisone as First Line Treatment and Thalidomide-Interferon vs. Interferon Maintenance Therapy in Elderly Patients with Multiple Myeloma.

Heinz Ludwig, MD, Elena Tothova, MD, Roman Hajek, MD, Johannes Drach, MD, Zdenek Adam, MD, Boris Labar, MD, Miklós Egyed, MD, Ivan Spicka, MD, Heinz Gisslinger, MD, Ingrid Kuhn, MD, Axel Hinke, PhD

Blood (2007) 110 (11): 529.

https://doi.org/10.1182/blood.V110.11.529.529

Published: 2007

Journal Articles

Rapid Remission Induction by VTD (Velcade, Thalidomide, Dexamethason) in Patients with Multiple Myeloma and High Tumor Burden at Diagnosis.

Viktoria Odelga, MD, Jutta Ackermann, Verena Sagaster, MD, Hannes Kaufmann, MD, Christoph Zielinski, MD, Johannes Drach, MD

Blood (2007) 110 (11): 4845.

https://doi.org/10.1182/blood.V110.11.4845.4845

Published: 2007

Journal Articles

Prospective, Randomized Comparison between Double Transplantation (T) with Melphalan (200 mg/m 2 ) and Triple T with Intermediate Dose Melphalan (100 mg/m 2 ) in Patients with Multiple Myeloma (An Interim Analysis).

Heinz Ludwig, MD, Werner Linkesch, MD, Hedwig Kasparu, MD, Otto Krieger, MD, Ivan Spicka, MD, Gunther Gastl, MD, Richard Greil, MD, Johannes Drach, MD, Josef Thaler, MD, Ingrid Kuhn, Niklas Zojer, MD, Axel Hinke, PhD

Blood (2006) 108 (11): 3083.

https://doi.org/10.1182/blood.V108.11.3083.3083

Published: 2006

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Efficacy and Safety of Frontline Bortezomib, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (VR-CAP) Vs R-CHOP in a Subset of Newly Diagnosed Mantle Cell Lymphoma (MCL) Patients (Pts) Medically Eligible for Transplantation in the Randomized Phase 3 LYM-3002 Study (NCT00722137)

Updated Efficacy and Safety, and Exploratory Ki-67 Results For The MCL-001 Study Of Lenalidomide In Mantle Cell Lymphoma Patients Who Relapsed Or Were Refractory To Bortezomib

Phase II Multicenter Study of Single-Agent Lenalidomide in Subjects with Mantle Cell Lymphoma Who Relapsed or Progressed After or Were Refractory to Bortezomib: The MCL-001 “EMERGE” Study

Induction Therapy with Novel Agents Improves Relapse-Free Survival After Autologous Stem-Cell Transplantation in Multiple Myeloma

Bortezomib Administered Subcutaneously Is Well Tolerated in Bortezomib-Based Combination Regimens Used in Patients with Multiple Myeloma and AL Amyloidosis

UDP Glucuronosyltransferase 2B17 Double Deletion Genotype Is An Independent Marker for Poor Prognosis In Multiple Myeloma

Secretome Analyses of Primary Bone Marrow Fibroblasts Isolated From MGUS and Multiple Myeloma Show a Stepwise Occurrence of Alterations.

Efficacy and Safety of Retreatment with Bortezomib in Patients with Multiple Myeloma: Interim Results From RETRIEVE, a Prospective International Phase 2 Study.

Efficacy of the Combination of Bortezomib and Dexamethasone in Systemic AL Amyloidosis.

Thalidomide-Interferon Vs. Interferon Maintenance Therapy After Thal-Dex Vs. MP Induction Therapy in Elderly Patients with Multiple Myeloma.

Thalidomide-dexamethasone compared with melphalan-prednisolone in elderly patients with multiple myeloma

Double Transplantation with Melphalan (200 mg/m 2 ) Compared with Triple Transplantation with Intermediate Dose Melphalan (100 mg/m 2 ) in Patients with Multiple Myeloma

Two-Monthly Rituximab Infusions Maintain Target Concentrations: Pharmacokinetic Data of the AGMT-NHL9 Maintenance Study in Patients with Follicular Lymphoma in Complete or Partial Remission.

Predictive Value of D-Dimer Levels for Venous Thromboembolism in Cancer Patients: Results from the Vienna Cancer and Thrombosis Study (CATS)

Efficacy and Safety of Re-Treatment with Bortezomib (Velcade©) in Patients with Multiple Myeloma: Results from a Prospective International Phase II Trial

A Cellular Proteome Map of Human Multiple Myeloma.

Bortezomib, Rituximab, and Dexamethason (BORID) as Salvage Treatment in Relapsed/Refractory Mantle Cell Lymphoma: Sustained Disease Control in Patients Achieving a Complete Remission.

Thalidomide-Dexamethasone vs. Melphalan-Prednisone as First Line Treatment and Thalidomide-Interferon vs. Interferon Maintenance Therapy in Elderly Patients with Multiple Myeloma.

Rapid Remission Induction by VTD (Velcade, Thalidomide, Dexamethason) in Patients with Multiple Myeloma and High Tumor Burden at Diagnosis.

Prospective, Randomized Comparison between Double Transplantation (T) with Melphalan (200 mg/m 2 ) and Triple T with Intermediate Dose Melphalan (100 mg/m 2 ) in Patients with Multiple Myeloma (An Interim Analysis).

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only